Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome

NCT02670525 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02670525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
August 17, 2016
Completion date
January 31, 2028
Enrollment
338 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

matched targeted therapy, recurrent, refractory, or high risk leukemias